entertainment -WSS

entertainment

author：comprehensive 2025-10-01 20:15:59 - browse：83

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The Sacklers, horror, and ‘The Fall of the House of Usher’

WSS

Head of FDA's diagnostics center, who led through Covid, retires

Just how powerful is the placebo effect?

More doctors should go into startup world

White House calls on federal agencies to crack down on AI abuses

Abortion clinic in Cancun will cater to Americans

Abortion clinic in Cancun will cater to Americans

hotspot

entertainment

entertainment

Alkermes shareholders re

10 million people disenrolled from Medicaid over past six months

State Dept. review finds Biden bears some blame for Afghanistan failures

Maisha Meds is a PBM, but don't call it that

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Trump demands the U.S. pay no more for drugs than other countries … again

Mass General, Mayo Clinic look to monetize custom

Novavax promises a turnaround & Lilly roils the obesity market

Will General Catalyst be the first of many hospital takeovers?

Wikipedia

There's an unseen cost to disruptive road

Study: New antibiotic targets gonorrhea as well as last existing drug

What causes osteoarthritis? Researchers study link to brain protein

What causes osteoarthritis? Researchers study link to brain protein

Biotech incubator Curie.Bio graduates its first startup

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

focus

focus

hotspot

leisure time